A promoter polymorphism in the interferon α-2 gene is associated with the clinical presentation of hepatitis B

Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis

Volumn 601, Issue 1-2, 2006, Pages 137-143

  Song, Le H ^a,b   Toan, Nguyen L ^a   Xuan, Nguyen T ^a   Uhlemann, Anne Catrin ^a   Boldt, Angelica B W ^a   Duy, Dinh N ^b   Binh, Vu Q ^b   Kremsner, Peter G ^a,c   Kun, Jürgen F J ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b Tran Hung Dao Hospital   (Viet Nam)

^c ALBERT SCHWEITZER HOSPITAL   (Gabon)

Author keywords

Hepatitis B; Interferon alpha; Susceptibility; Vietnam

Indexed keywords

ALPHA2 INTERFERON;

ARTICLE; CLINICAL FEATURE; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; FREQUENCY ANALYSIS; GENE DELETION; GENE MUTATION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENETIC TRANSCRIPTION; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IN VITRO STUDY; INFECTION SENSITIVITY; MAJOR CLINICAL STUDY; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROMOTER REGION; REPORTER GENE; STATISTICAL SIGNIFICANCE; VIET NAM; WILD TYPE;

ADULT; BASE SEQUENCE; CELLS, CULTURED; GENETIC PREDISPOSITION TO DISEASE; HEPATITIS B; HUMANS; INTERFERON-ALPHA; LIVER; LUCIFERASES; MIDDLE AGED; MOLECULAR SEQUENCE DATA; POLYMORPHISM, GENETIC; PROMOTER REGIONS (GENETICS); PROMOTER REGIONS, GENETIC; RECOMBINANT FUSION PROTEINS; SEQUENCE ANALYSIS, DNA; VIETNAM;

HEPATITIS B VIRUS;

EID: 33749673394     PISSN: 00275107     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mrfmmm.2006.06.011     Document Type: Article

References (27)

1. Wang F.S. Current status and prospects of studies on human genetic alleles associated with hepatitis B virus infection. World J. Gastroenterol. 9 (2003) 641-644
2. Chong W.P., To Y.F., Ip W.K., Yuen M.F., Poon T.P., Wong W.H., Lai C.L., and Lau Y.L. Mannose-binding lectin in chronic hepatitis B virus infection. Hepatology 42 (2005) 1037-1045
3. Bellamy R., Ruwende C., Corrah T., McAdam K.P., Thursz M., Whittle H.C., and Hill A.V. Tuberculosis and chronic hepatitis B virus infection in Africans and variation in the vitamin D receptor gene. J. Infect. Dis. 179 (1999) 721-724
4. Karayiannis P. Hepatitis B virus: old, new and future approaches to antiviral treatment. J. Antimicrob. Chemother. 51 (2003) 761-785
5. Cavanaugh V.J., Guidotti L.G., and Chisari F.V. Inhibition of hepatitis B virus replication during adenovirus and cytomegalovirus infections in transgenic mice. J. Virol. 72 (1998) 2630-2637
6. Diaz M.O., Pomykala H.M., Bohlander S.K., Maltepe E., Malik K., Brownstein B., and Olopade O.I. Structure of the human type-I interferon gene cluster determined from a YAC clone contig. Genomics 22 (1994) 540-552
7. Rubinstein M., Levy W.P., Moschera J.A., Lai C.Y., Hershberg R.D., Bartlett R.T., and Pestka S. Human leukocyte interferon: isolation and characterization of several molecular forms. Arch. Biochem. Biophys. 210 (1981) 307-318
8. Pestka S., Krause C.D., Sarkar D., Walter M.R., Shi Y., and Fisher P.B. Interleukin-10 and related cytokines and receptors. Annu. Rev. Immunol. 22 (2004) 929-979
9. Buti M., and Esteban R. Drugs in development for hepatitis B. Drugs 65 (2005) 1451-1460
10. Cooksley W.G. Peginterferon alpha-2a for the treatment of hepatitis B infection. Expert Opin. Pharmacother. 6 (2005) 1373-1380
11. Guan R. Treatment of chronic hepatitis B infection using interferon. Med. J. Malaysia 60 Suppl. B (2005) 28-33
12. Hiscott J., Cantell K., and Weissmann C. Differential expression of human interferon genes. Nucleic Acids Res. 12 (1984) 3727-3746
13. Uno K., Suginoshita Y., Kakimi K., Moriyasu F., Hirosaki M., Shirakawa T., and Kishida T. Impairment of IFN-alpha production capacity in patients with hepatitis C virus and the risk of the development of hepatocellular carcinoma. World J. Gastroenterol. 11 (2005) 7330-7334
14. Song L.H., Binh V.Q., Duy D.N., Jüliger S., Bock T.C., Luty A.J., Kremsner P.G., and Kun J.F.J. Mannose-binding lectin gene polymorphisms and hepatitis B virus infection in Vietnamese patients. Mutat. Res. 522 (2003) 119-125
15. Jüliger S., Bongartz M., Luty A.J., Kremsner P.G., and Kun J.F.J. Functional analysis of a promoter variant of the gene encoding the interferon-gamma receptor chain I. Immunogenetics 54 (2003) 675-680
16. den Dunnen J.T., and Antonarakis S.E. Mutation nomenclature extensions and suggestions to describe complex mutations: a discussion. Hum. Mutat. 15 (2000) 7-12
17. de Andrade Jr. D.R., and de Andrade D.R. The influence of the human genome on chronic viral hepatitis outcome. Rev. Inst. Med. Trop. Sao Paulo 46 (2004) 119-126
18. Höhler T., Kruger A., Gerken G., Schneider P.M., Meyer zum Büschenfelde K.H., and Rittner C. A tumor necrosis factor-alpha (TNF-alpha) promoter polymorphism is associated with chronic hepatitis B infection. Clin. Exp. Immunol. 111 (1998) 579-582
19. Krämer H., Niemöller M., Amouyal M., Revet B., Wilcken-Bergmann B., and Müller-Hill B. Lac repressor forms loops with linear DNA carrying two suitably spaced lac operators. EMBO J. 6 (1987) 1481-1491
20. Lewis D.E., and Adhya S. In vitro repression of the gal promoters by GalR and HU depends on the proper helical phasing of the two operators. J. Biol. Chem. 277 (2002) 2498-2504
21. Barthel R., Tsytsykova A.V., Barczak A.K., Tsai E.Y., Dascher C.C., Brenner M.B., and Goldfeld A.E. Regulation of tumor necrosis factor alpha gene expression by mycobacteria involves the assembly of a unique enhanceosome dependent on the coactivator proteins CBP/p300. Mol. Cell Biol. 23 (2003) 526-533
22. Uhlemann A.C., Szlezak N.A., Vonthein R., Tomiuk J., Emmer S.A., Lell B., Kremsner P.G., and Kun J.F.J. DNA phasing by TA dinucleotide microsatellite length determines in vitro and in vivo expression of the gp91phox subunit of NADPH oxidase and mediates protection against severe malaria. J. Infect. Dis. 189 (2004) 2227-2234
23. Miyazoe S., Hamasaki K., Nakata K., Kajiya Y., Kitajima K., Nakao K., Daikoku M., Yatsuhashi H., Koga M., Yano M., and Eguchi K. Influence of interleukin-10 gene promoter polymorphisms on disease progression in patients chronically infected with hepatitis B virus. Am. J. Gastroenterol. 97 (2002) 2086-2092
24. Ben Ari Z., Mor E., Papo O., Kfir B., Sulkes J., Tambur A.R., Tur-Kaspa R., and Klein T. Cytokine gene polymorphisms in patients infected with hepatitis B virus. Am. J. Gastroenterol. 98 (2003) 144-150
25. Muir A.J., Bornstein J.D., and Killenberg P.G. Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. N. Engl. J. Med. 350 (2004) 2265-2271
26. Marcellin P., Lau G.K.K., Bonino F., Farci P., Hadziyannis S., Jin R., Lu Z.M., Piratvisuth T., Germanidis G., Yurdaydin C., Diago M., Gurel S., Lai M.Y., Button P., Pluck N., and and the Peginterferon alfa-2a HBeAg-Negative Chronic Hepatitis B Study Group. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N. Engl. J. Med. 351 (2004) 1206-1217
27. Janssen H.L., van Zonneveld M., Senturk H., Zeuzem S., Akarca U.S., Cakaloglu Y., Simon C., So T.M., Gerken G., and de Man R.A. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet 365 (2005) 123-129